Get started
Author

Farah Shanoon

Observed names: F. Shanoon, FARAH SHANOON, Shanoon, Farah
OpenAlex ID: A5064200550
“Asymptomatic” persistent or permanent atrial fibrillation: A misnomer in selected patients
2015 · Anand V. Ganapathy, Seena Monjazeb, et al. · International Journal of Cardiology · 32
Cryoballoon Pressure Waveform Change during Balloon Inflation is not a Reliable Predictor of Adequate Pulmonary Vein Occlusion
2014 · PAYAM SAFAVI‐NAEINI, FARAH SHANOON, et al. · Pacing and Clinical Electrophysiology · 16
First clinical experience using targeted alpha-emitter therapy with 212Pb-DOTAMTATE (AlphaMedix TM) in patients with SSTR(+) neuroendocrine tumors.
2019 · Ebrahim S. Delpassand, Izabela Tworowska, et al. · Journal of Nuclear Medicine · 10
Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)
2019 · Izabela Tworowska, Ebrahim S. Delpassand, et al. · Journal of medical imaging and radiation sciences · 3
Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)
2019 · Izabela Tworowska, Ebrahim S. Delpassand, et al. · Journal of medical imaging and radiation sciences · 3
PDF
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
2025 · Balazs Halmos, Narjust Florez, et al. · Oncology and Therapy · 2
PDF
Abstract CT159: First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors
2020 · Izabela Tworowska, Ebrahim S. Delpassand, et al. · Cancer Research · 2
MO12.09: Subcutaneous Amivantamab+Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up From the Pragmatic COPERNICUS Study
2026 · B. Halmos, J. Tu, et al. · Journal of Thoracic Oncology
COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in EGFR -mutated advanced NSCLC: Early safety results.
2026 · Sarah B. Goldberg, Balazs Halmos, et al. · Journal of Clinical Oncology
COPERNICUS, a pragmatic phase 2b study of subcutaneous (SC) amivantamab (ami) + chemotherapy (chemo) with enhanced dermatologic adverse event (AE) prophylaxis in EGFR -mutated advanced NSCLC: Interim results.
2026 · Ticiana Leal, Balazs Halmos, et al. · Journal of Clinical Oncology
289 COPERNICUS: A Multinational Pragmatic Phase 2 Trial of Subcutaneous (SC) Amivantamab (Ami) in Common EGFR-Mutated (cEGFRm) NSCLC
2026 · Anna Minchom, Balazs Halmos, et al. · Lung Cancer
2082eTiP COPERNICUS: A multinational pragmatic phase II trial of subcutaneous (SC) amivantamab (Ami) in common EGFR-mutated (cEGFRm) NSCLC
2025 · B. Halmos, N. Florez, et al. · Annals of Oncology
P3623Anti-arrhythmic effects seen with lariat is not associated with reverse remodeling
2017 · I. Basu Ray, K. Khalid, et al. · European Heart Journal
Abstract 15707: Change in Cryo-Balloon Pressure Waveforms during Balloon Inflation is Poorly Correlated with Pulmonary Vein Occlusion
2012 · Farah Shanoon, Rohit Kedia, et al. · Circulation
Works count: 14
Citation count: 67
H-index: 3
I10-index: 3
Year
Topic
Type